Understanding who leads the global Animal Health Market, how they got there, where they are investing, and where they are most vulnerable has never been more critical. Zoetis returned $4.1 billion to shareholders in 2025 while pivoting toward feline chronic kidney disease — a $3-4 billion addressable opportunity — and launching Leniva, the long-acting monoclonal antibody for canine osteoarthritis pain. Merck Animal Health gained FDA approval for BRAVECTO QUANTUM, the first once-yearly injectable parasiticide for dogs, and announced an $895 million expansion of its De Soto, Kansas biologics facility. Boehringer Ingelheim's NEXGARD reached $1.5 billion in 2025 sales, cementing its position as the industry's top-selling parasiticide brand. Phibro Animal Health acquired Zoetis's medicated feed additive portfolio for $350 million, growing fiscal 2025 revenue 27% to $1.3 billion. Combined revenues of the top 10 animal health companies grew at mid-to-high single digits in 2025, outpacing the broader pharmaceutical industry.

This report provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs.

Companies Analyzed in This Report:
Boehringer Ingelheim Animal Health
Ceva Santé Animale
Dechra Pharmaceuticals
Elanco Animal Health
IDEXX Laboratories
Merck Animal Health
Phibro Animal Health
Vetoquinol
Virbac
Zoetis

The Analysis of Each Company Includes:
• Strategic Directions and Corporate Priorities
• Financial Performance and Revenue Breakdown
• SWOT Analysis
• Technological Know-How and Innovation Programs
• Latest Products and Services
• M&A, Partnerships and Alliances
• Marketing Tactics and Commercial Strategy
• Organization and Management Structure

Topics Covered
• Financial Performance
• SWOT Analysis
• Technological Know-How
• Latest Products and Services
• M&A and Partnerships
• Marketing Tactics
• Organization and Management